ArticleThe primary care companion for CNS disorders2015
Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia: A Systematic Review of Efficacy and Safety.
Article in The primary care companion for CNS disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder.British journal of clinical pharmacology · 2026Trial
- A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal Doxylamine in Subjects with Chronic Intermittent Sleep Impairment.Drugs in R&D · 2018Trial
- Assessment of depression, PTSD, and insomnia symptoms in a cohort of Palestinian migrants residing in Jordanian camps during the outbreak of the War on Gaza: occurrence and correlates.Discover mental health · 2025Article
- Factors associated with insomnia and fatigue symptoms during the outbreak of Oct.7th war on Gaza: A study from Jordan.Preventive medicine reports · 2024Article
- Pharmacological management of pediatric insomnia.Frontiers in sleep · 2024Review
- Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.The mental health clinician · 2023Review
- Factors associated with the use of over-the-counter sleep aids containing diphenhydramine: A cross-sectional study in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Counselling for Chronic Insomnia in Swiss Pharmacies: A Survey Study Based on Case Vignettes.Pharmacy (Basel, Switzerland) · 2023Article
- Improving sleep health management in primary care: A potential role for community nurses?Journal of advanced nursing · 2023Article
- Prevalence and Risk Factors of Insomnia and Sleep-aid Use in Emergency Physicians in Japan: Secondary Analysis of a Nationwide Survey.The western journal of emergency medicine · 2023Article
- Sleep medication use and incident dementia in a nationally representative sample of older adults in the US.Sleep medicine · 2021Article
- Exploring the Prevalence and Patterns of Use of Sleep Aids and Stimulants Among Emergency Physicians and EMS Providers in Saudi Arabia.Open access emergency medicine : OAEM · 2021Article
- A combination ofJournal of traditional and complementary medicine · 2020Article
- Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews.Systematic reviews · 2019Review
- Treating psychiatric symptoms and disorders with non-psychotropic medications .Dialogues in clinical neuroscience · 2019Review
- Managing sleep problems using non-prescription medications and the role of community pharmacists: older adults' perspectives.The International journal of pharmacy practice · 2017Article
- Insomnia: A Current Review.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the level of evidence supporting the use of common over-the-counter (OTC) agents (diphenhydramine, doxylamine, melatonin, and valerian) for occasional disturbed sleep or insomnia. DATA SOURCES: A systematic review of the literature was conducted on July 31, 2014, using MEDLINE (PubMed) and the search terms (insomnia OR sleep) AND (over*the*counter OR OTC OR non*prescription OR antihistamine OR doxylamine OR diphenhydramine OR melatonin OR valerian) with the filters English, human, and clinical trials. STUDY SELECTION: Identified publications (from 2003 to July 31, 2014, following previous published literature reviews) that met the inclusion criteria were selected. The criteria included randomized placebo-controlled clinical studies that utilized overnight objective (polysomnography) or next-day participant-reported sleep-related endpoints and that were conducted in healthy participants with or without occasional disturbed sleep or diagnosed insomnia.
resultsMeasures of efficacy and tolerability were summarized for each study individually and grouped according to OTC agent: H1 antagonists or antihistamines (3 studies, diphenhydramine), melatonin (8), and valerian or valerian/hops (7). Of the 3 sleep agents, studies conducted with melatonin, especially prolonged-release formulations in older individuals with diagnosed insomnia, demonstrated the most consistent beneficial effects (vs placebo) on sleep measures, specifically sleep onset and sleep quality, with favorable tolerability. In contrast, the clinical trial data for diphenhydramine, immediate-release melatonin, and valerian suggested limited beneficial effects.
conclusionsA review of randomized controlled studies over the past 12 years suggests commonly used OTC sleep-aid agents, especially diphenhydamine and valerian, lack robust clinical evidence supporting efficacy and safety.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.